Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,379 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diabetes Diagnosis Clear all
Not listed Not applicable Interventional

The Management of Diabetes in Everyday Life Program

NCT02957513
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Disease
Interventions
Text Messaging (TM), Health Coaching (HC), Enhanced Usual Care (EC)
Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Holly Springs, Mississippi • Bartlett, Tennessee • Covington, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 17, 2026, 9:03 AM EDT
Recruiting No phase listed Observational

A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction

NCT05332262
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Assessment of platelet reactivity, Troponin measurement
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

NCT02357420
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
Relamorelin, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
70
States / cities
Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

NCT06354660
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Canoga Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Not applicable Interventional

iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes

NCT02980627
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Eating Disorders
Interventions
Therapy with Mobile App Enhancement
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 17, 2026, 9:03 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

NCT05480657
View directory record Official record
Conditions
Brittle Type 1 Diabetes Mellitus
Interventions
AT-1501 IV Infusion, Isolated cadaveric islet cells
Biological
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 17, 2026, 9:03 AM EDT
Withdrawn Phase 1 Interventional

A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus

NCT00214214
View directory record Official record
Conditions
New Onset Type 1 Diabetes Mellitus
Interventions
Campath 1H® (Alemtuzumab)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 17, 2026, 9:03 AM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus

NCT00228891
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Effect of Pulsatile IV Insulin on diabetic neuropathy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 17, 2026, 9:03 AM EDT
Completed No phase listed Observational

Metabolic Phenotypes and Heterogeneity in Disease Burden Risk in Type 1 Diabetes

NCT05609279
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 17, 2026, 9:03 AM EDT
Completed No phase listed Observational

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT06587828
View directory record Official record
Conditions
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
Interventions
Companion blood samples with procedure
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 9:03 AM EDT
Not listed Not applicable Interventional

Chronicare for Type 2 Diabetes (Chronicare-T2D)

NCT03997331
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
CRx Health, Chronicare
Other
Lead sponsor
QuiO
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Midland, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

NCT01354977
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Resveratrol
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Integrating Lifestyle Therapy for Diabetes Prevention Into Primary Care

NCT00853801
View directory record Official record
Conditions
Pre-Diabetes, Metabolic Syndrome, Type 2 Diabetes
Interventions
Lifestyle intervention and provider feedback
Behavioral
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 17, 2026, 9:03 AM EDT
Withdrawn Phase 3 Interventional

Empaglifozin in Early Diabetic Kidney Disease

NCT03173963
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Mellitus Type 2
Interventions
Empagliflozin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stroke Prevention in the Wisconsin Native American Population

NCT04382963
View directory record Official record
Conditions
Stroke, Atherosclerosis
Interventions
High Risk - intensive coaching, High Risk - standard care, Low Risk - control
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Madison, Wisconsin • Oneida, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Latinos Understanding the Need for Adherence

NCT02955238
View directory record Official record
Conditions
Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions
Special Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
40 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Phase 4 Interventional

INVEST: INternational VErapamil SR Trandolapril STudy

NCT00133692
View directory record Official record
Conditions
Hypertension, Coronary Artery Disease
Interventions
Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril
Drug
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
22,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 17, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind

NCT03024944
View directory record Official record
Conditions
Diabetes Mellitus, Alzheimer Dementia
Interventions
18F-THK-5351
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Walnut Consumption, Endothelial Function, and Biomarkers

NCT01884363
View directory record Official record
Conditions
Coronary Heart Disease, Type 2 Diabetes
Interventions
Once ounce per day of walnuts
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2016 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone in Thyroid Cancers

NCT01655719
View directory record Official record
Conditions
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
Interventions
Pioglitazone
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 17, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting

NCT02463682
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
CGM and Insulin Pump, Closed-Loop Control System
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 17, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

Culturally Tailored Program for Food-Insecure Adults: SPICE-D

NCT07361341
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2D)
Interventions
Food Bundle Intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 17, 2026, 9:03 AM EDT